<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580615</url>
  </required_header>
  <id_info>
    <org_study_id>CL00450</org_study_id>
    <nct_id>NCT04580615</nct_id>
  </id_info>
  <brief_title>Data Collection From the CardiacSense1 and Other Modalities for Developing a System for Monitoring of Respiratory Rate</brief_title>
  <official_title>Anonymized Data Collection From the CardiacSense1 and Other Modalities for the Purpose of Developing a System for Monitoring of Respiratory Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardiacSense Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardiacSense Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collect data from the CardiacSense1's sensors and Capnograph, for the purpose of developing a&#xD;
      wearable system for monitoring of Respiratory Rate (RR) in patients while at hospital&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hospitalized subjects, diagnosed with a Respiratory disease or subjects with no known&#xD;
      Respiratory disease will be will be connected simultaneously to CardiacSense watch and&#xD;
      Capnograph for a duration of at least 30 minutes and up to 24 hours in order to collect data&#xD;
      for the purpose of developing a wearable system for monitoring of Respiratory Rate (RR) by&#xD;
      the CardiacSense watch.&#xD;
&#xD;
      The CardiacSense1 is a wrist worn device designed to detect atrial fibrillation.&#xD;
      CardiacSense1 senses the radial artery inflation and deflation and together with a PPG&#xD;
      sensors give an ultimate performance that is superior to PPG only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>24 hours</time_frame>
    <description>Capnograph and Cardiacsense1 sensor Respiratory rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Inpatients subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inpatients subjects diagnosed with a Respiratory disease/impairment or subjects with no known Respiratory disease/impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardiacSense1 and capnograph Respiratory rate measurement</intervention_name>
    <description>Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.</description>
    <arm_group_label>Inpatients subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of eighteen (18) year and above&#xD;
&#xD;
          -  Diagnosed with Respiratory disease/impairment or without any known Respiratory&#xD;
             disease/impairment&#xD;
&#xD;
          -  Ability and willingness to sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are currently enrolled in another clinical investigation in which the&#xD;
             intervention might compromise the safety of the subject's participation in this study&#xD;
&#xD;
          -  Patients with significant co morbidities (assessed by the clinician at screening only&#xD;
&#xD;
          -  BMI&gt;40&#xD;
&#xD;
          -  Presence of an acute disease process that might interfere with test performance&#xD;
&#xD;
          -  Subjects with PPG SNR &lt;100 indicated by the CardiacSense1 device&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giris Jacob, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giris Jacob, MD</last_name>
    <phone>036973974</phone>
    <email>jacobgi@tlvmc.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>62431</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giris Jacob, MD</last_name>
      <phone>036973974</phone>
      <email>jacobgi@tlvmc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD to be shared with other researcher</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

